文献速递心律失常心力衰竭与心肌病

一种用于桥粒斑蛋白基因变异携带者心律失常风险分层的新工具

A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers.
PubMed 文献 · Eur Heart J · 2024-01-01

本研究基于多国DSP-ERADOS注册研究,纳入471例携带致病性或可能致病性DSP基因变异且入组前无持续性室性心律失常的患者,随访中位4.0年,71例发生首次持续性VA事件(2.6%/年,95%CI 2.0-3.5)。

要点

  • DSP风险评分基于5个常规临床参数,可用于个体化持续性VA风险评估。
  • 外部验证队列中低危组(5年VA风险<5%,n=26)阴性预测值为100%。
  • 该工具可能有助于指导该高危人群的一级预防ICD植入决策。

核心结论

  • DSP风险评分是一种利用常规临床参数为DSP患者提供个体化VA风险评估的新模型。
  • 该工具可能有助于指导该高危人群的一级预防ICD植入决策,并支持基因优先的风险分层策略。

研究设计与样本

  • 多国DSP-ERADOS注册研究,纳入携带致病性或可能致病性DSP变异且入组前无持续性VA的患者。
  • 采用临床导向的逐步Cox回归分析开发预测新发VA的临床工具。
  • 模型开发队列n=385,外部验证队列n=86,总样本471例。

主要发现

  • 共471例DSP患者,平均年龄37.8岁,65.6%为女性,38.6%为先证者,26% LVEF<50%。
  • 中位随访4.0年(IQR 1.6-7.3),71例发生首次持续性VA事件,发生率2.6%/年(95%CI 2.0-3.5)。
  • 外部验证队列中低危患者(5年VA风险<5%,n=26)的阴性预测值为100%。

临床怎么用

  • 对于携带致病性或可能致病性DSP变异的患者,可使用DSP风险评分进行个体化持续性VA风险评估。
  • 评分可能辅助识别适合接受一级预防ICD植入的高危患者,低危患者或可避免不必要植入。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Pathogenic desmoplakin (DSP) gene variants are associated with the development of a distinct form of arrhythmogenic cardiomyopathy known as DSP cardiomyopathy. Patients harbouring these variants are at high risk for sustained ventricular arrhythmia (VA), but existing tools for individualized arrhythmic risk assessment have proven unreliable in this population. METHODS: Patients from the multi-national DSP-ERADOS (Desmoplakin SPecific Effort for a RAre Disease Outcome Study) Network patient registry who had pathogenic or likely pathogenic DSP variants and no sustained VA prior to enrolment were followed longitudinally for the development of first sustained VA event. Clinically guided, step-wise Cox regression analysis was used to develop a novel clinical tool predicting the development of incident VA. Model performance was assessed by c-statistic in both the model development cohort (n = 385) and in an external validation cohort (n = 86). RESULTS: In total, 471 DSP patients [mean age 37.8 years, 65.6% women, 38.6% probands, 26% with left ventricular ejection fraction (LVEF) < 50%] were followed for a median of 4.0 (interquartile range: 1.6-7.3) years; 71 experienced first sustained VA events {2.6% [95% confidence interval (CI): 2.0, 3.5] events/year}. Within the development cohort, five readily available clinical parameters were identified as independent predictors of VA and included in a novel DSP risk score: female sex [hazard ratio (HR) 1.9 (95% CI: 1.1-3.4)], history of non-sustained ventricular tachycardia [HR 1.7 (95% CI: 1.1-2.8)], natural logarithm of 24-h premature ventricular contraction burden [HR 1.3 (95% CI: 1.1-1.4)], LVEF < 50% [HR 1.5 (95% CI: .95-2.5)], and presence of moderate to severe right ventricular systolic dysfunction [HR 6.0 (95% CI: 2.9-12.5)]. The model demonstrated good risk discrimination within both the development [c-statistic .782 (95% CI: .77-.80)] and external validation [c-statistic .791 (95% CI: .75-.83)] cohorts. The negative predictive value for DSP patients in the external validation cohort deemed to be at low risk for VA (<5% at 5 years; n = 26) was 100%. CONCLUSIONS: The DSP risk score is a novel model that leverages readily available clinical parameters to provide individualized VA risk assessment for DSP patients. This tool may help guide decision-making for primary prevention implantable cardioverter-defibrillator placement in this high-risk population and supports a gene-first risk stratification approach.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Carrick RT, Gasperetti A, Protonotarios A, et al. A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers. Eur Heart J. 2024. PMID: 39011630. doi:10.1093/eurheartj/ehae409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。